Redeye views I-Tech’s Q3 as showing healthy progress, with top-line growth of 19% and an EBITDA margin of 31%. Still, the figures were somewhat lower than our high expectations following the record results posted in Q2’26. The company continues to cost-efficiently broaden its pipeline with new acquisitions and licensing deals, while an EU-BPR outcome is now expected in the near term with legal dispute prepared in case of a negative outcome. Based on our initial take, we expect to make minor negative estimate revisions, although we remain positive regarding the company's progress and outlook as a whole.
LÄS MER
